In a blow to the development of anti-TIGIT immunotherapies, Merck's combination treatment of new immunotherapy drug, vibostolimab, and its established drug, Keytruda, failed to significantly slow disease progression or improve overall survival in lung cancer patients. Read more about the trial results and the future plans of Merck in this article.
English (US) ·